Showing: 1 - 5 of 5 RESULTS
Briefing Ketamine News Pharmather Psychedelics

PharmaTher Acquires Exclusive Rights To Patented Ketamine Formulation

PharmaTher Inc (CSE: PHRM) has entered into an exclusive worldwide license agreement for the development and commercialization of a patented formulation of FDA-approved ketamine and betaine. The product is being viewed as a potential next-generation treatment for neurological and pain disorders as well as mental health. The arrangement was entered into with the National Health …

Briefing Fabio Chianelli Ketamine Pharmather Psychedelics Video Series

Artificial Intelligence Meets Psychedelics – The Daily Dive feat Fabio Chianelli

Today on the Daily Dive, Fabio Chianelli, CEO of PharmaTher Inc (CSE: PHRM) sits down with our host Cassandra Leah to discuss the company as well as the psychedelic space in general. Within, he discusses his outlook for the growing psychedelic renaissance as well as the direction that PharmaTher is headed in terms of research …

Briefing Champignon Brands Harvest Moon Research Johnson & Johnson Ketamine Psychedelics

Harvest Moon: Reducing Suicidal Ideation With Ketamine Infusions

Suicidal ideation is an emergent condition that demands immediate attention. It has been shown that the time between decision and attempt in patients with suicidal ideations is about ten minutes. Suicide ranks among the top three causes of mortality worldwide for individuals ages 15–44. Unfortunately, the suicide rate has increased over the past two decades …